In order to assess the effect of delaying G-CSF administration after autologous peripheral blood progenitor cell (PBPC) transplantation on the duration of neutropenia, 87 patients were randomized to receive G-CSF 5 g/kg/day starting on day +1 (n = 45) or +5 (n = 42) following PBPC transplantation, until recovery of the neutrophils. The duration of neutropenia (Ͻ0.5 ؋ 10 9 /l) was shorter in the day +1 group (7 vs 8 days; P = 0.02), especially in patients receiving melphalan 200 mg/m 2 and CD34
Several randomized and non-randomized trials have evaluated the use of granulocyte colony-stimulating factor (G-CSF), administered from the first day after transplant (day +1) until engraftment, in autologous bone marrow transplantation, [4] [5] [6] [7] [8] [9] as well as in peripheral blood progenitor cell (PBPC) transplantation. [10] [11] [12] [13] [14] [15] [16] In most of these studies, G-CSF accelerated neutrophil recovery, with mixed results in terms of reduction in infections and duration of hospital stay. However, the best timing for initiating hematopoietic growth factors after PBPC transplantation is still a matter of considerable debate, as evidenced by the numerous studies published to date on the subject of 'early' vs 'delayed' G-CSF administration. [17] [18] [19] [20] The rationale for delaying the start of G-CSF, besides the obvious issue of cost restriction, lies in its preferential action upon more differentiated, committed granulocytic precursors. Immature pluripotent stem cells have few G-CSF receptors and they take approximately 7 days to differentiate into highly G-CSF-responsible granulocytic precursors. In a previous retrospective single-center study, we observed that delaying the start of G-CSF administration until day +5 was not associated with a longer duration of neutropenia, antibiotic therapy or hospital stay, when compared to G-CSF starting on day +1. 21 However, other studies have found earlier administration to be more beneficial. 22 The aim of the present study was to investigate these issues in a prospective, randomized, multicentric study.
Patients and methods

Patients
This multicentric, randomized trial was conducted at the University Hospitals of Universidade Estadual de Campinas (Campinas, SP, Brazil), Universidade de São Paulo (Ribeirão Preto, SP, Brazil), Universidade Federal do Rio de Janeiro (Rio de Janeiro, RJ, Brazil) and Hospital do Cân-cer, Instituto Nacional de Câncer (Rio de Janeiro, RJ, Brazil). Patients older than 12 years receiving an autologous PBPC transplantation were eligible. Exclusion criteria were the use of any cytokine or growth factor other than G-CSF, infusion of the total dose of PBPC in a time interval greater than 48 h, use of granulocyte transfusion before engraftment, or infusion of bone marrow cells. The study protocol was approved by the local ethics comittee of each institution, and written informed consent was obtained from each patient.
G-CSF administration, mobilization of PBPC, conditioning regimens and supportive care
Randomization was performed in blocks of 20 sealed envelopes that were sent to each institution separately, and opened on the day of PBPC infusion (day 0). Patients assigned to group A received daily G-CSF (Filgrastim; Roche, São Paulo, Brazil) as a 20-min i.v. infusion at a dose of 5 g/kg mixed in 20 ml of 5% dextrose in water, starting on day +1. Patients assigned to group B received Table 1 Characteristics of the patients and transplants the same dose of G-CSF, starting on day +5. G-CSF was given until the peripheral blood absolute neutrophil count (ANC) reached 1.5 ϫ 10 6 /l for 3 consecutive days. All patients received unmanipulated, cryopreserved PBPC harvested by leukapheresis. Enumeration of CD34 + cells was done as previously described. 23 Cells were thawed at the bedside and infused promptly through a central venous line.
Mobilization schedules and conditioning regimens were chosen according to the local protocols at each center, as listed in Table 1 .
Patients with Hodgkin's or non-Hodgkin's lymphoma were conditioned with BEAM (BCNU 300 mg/m i. 
Evaluation
Patients were evaluated at study entry by physical examination and standard biochemical tests. Automated complete blood counts and clinical evaluation were performed daily from the start of high-dose chemotherapy until discharge from the hospital. At least two blood cultures were drawn after the first febrile episode. Additional cultures, image studies and invasive diagnostic procedures were performed at the discretion of the attending physician.
Definitions
Duration of neutropenia was defined as the number of days with ANC у0.5 ϫ 10 9 /l. Time to neutrophil engraftment was defined as the number of days from day 0 until the first day with ANC у0.5 ϫ 10 9 /l. Time to platelet engraftment was defined as the number of days from day 0 until the first day with an unsupported platelet count у50 ϫ 10 9 /l. Duration of antibiotic treatment was defined as the number of days of non-prophylactic parenteral or oral antimicrobial treatment (antibacterial, antifungal or antiviral drugs), including completion of treatment on an outpatient basis after discharge, when clinically indicated. Duration of hospitalization was defined as the number of days from day 0 until the day of hospital discharge. Neutropenic fever was defined as an axillary temperature above 38°C in the presence of ANC р0.5 ϫ 10 9 /l. Febrile episodes were classified as fever of unknown origin, microbiologically documented infection with or without bacteremia, or clinically documented infection, according to published criteria. 24 
Statistical analysis and sample size calculation
The primary endpoint was the effect of randomization assignment on the duration of neutropenia. Thirty-five patients were needed in each arm in order to detect a difference of at least 2 days in the duration of neutropenia, with a power of 80%. For all comparisons, two-tailed P values Bone Marrow Transplantation р0.05 were considered to be statistically significant. Categorical variables were analyzed by chi-square or Fisher's exact test. The Kruskall-Wallis test was used for comparison of unpaired continuous variables. Times to neutrophil engraftment, platelet engraftment, and hospital discharge were analyzed by the Kaplan-Meier method and compared by the log-rank test. The effect of multiple variables other than the randomization assignment on the duration of neutropenia was evaluated by multiple regression analysis. The CD34 + cell dose was studied as a continuous variable and as dichotomous categories with cutoff values at 1.0 ϫ 10 6 /kg intervals. Registration and analysis of data were done using Epi-Info 6.04 software (Centers for Disease Control, Atlanta, GA, USA) and SPSS 10.0 for Windows (SPSS, 1989 (SPSS, -1999 .
Results
Ninety patients were randomized to receive G-CSF starting either on day +1 (group A; 46 patients) or day +5 (group B; 44 patients). All patients had hematologic malignancies except one, who had a testicular cancer. Four patients were excluded from the final analysis: two in group A (one patient with acute promyelocytic leukemia who received cryopreserved bone marrow instead of PBPC, and one with Hodgkin's lymphoma who received PBPC on 3 consecutive days), and two in group B (one with Hodgkin's lymphoma who received granulocyte transfusions to treat a serious infection before PBPC engraftment, and one with nonHodgkin's lymphoma who received PBPC on 4 consecutive days). One patient with testicular cancer received two sequential transplants and was randomized twice; both transplants were included in the final analysis. As shown in Table 1 , the groups were well balanced regarding age, gender, underlying disease, presence of pre-transplant comorbidities, mobilization protocol, conditioning regimen, CD34
+ cell dose, performance status at day 0, use of antimicrobial prophylaxis, and intravenous access device.
Patients in group B received a median of 3 days less G-CSF treatment than patients in group A (7.5 days vs 10.5 days; P = 0.001). As shown in Table 2 , patients assigned to group A had a shorter duration of neutropenia (P = 0.02). On the other hand, time to neutrophil engraftment and time to platelet engraftment were not different between the two groups.
The number of patients who developed fever and the median number of days with fever were similar in both groups. Patients in group B had more febrile episodes where infection was documented clinically or microbiologically (63% vs 51%), but the difference was not statistically significant (P = 0.27). The median number of days on nonprophylactic antimicrobial treatment was 7 in group A and 10.5 in group B (P = 0.01). However, since patients with bacteremia also had a longer duration of antibiotic treatment (median, 13 days vs 9 days; P = 0.002), and since there were more patients with bacteremia in group B (44% vs 33%; P = 0.2), we analyzed the impact of the day of initiation of G-CSF in patients with or without bacteremia. In patients with bacteremia, there was no statistically significant difference in the duration of antibiotic treatment between group A and group B (10 days vs 13 days, P = 0.27), whereas in patients without bacteremia, the median duration of antibiotic treatment was 7 days in group A and 10 days in group B (P = 0.02). Neither the use nor the duration of non-prophylactic empiric antifungal therapy was different between the two groups. The median duration of hospitalization was 13 days in group A and 15 days in group B (P = 0.02). There were two deaths in group A and one in group B (P = 1.0). Infection-related death occurred in only one patient, in group B.
The effect of other variables on the primary outcome was evaluated. Patients who received melphalan 200 mg/m 2 for conditioning (all patients with multiple myeloma and one patient with amyloidosis) had a later onset (median, day +4 vs day +2; P Ͻ 0.001) and shorter duration of neutropenia (median, 6 days vs 8 days; P Ͻ 0.001) when compared to all the others. Likewise, patients who received more than 3.0 ϫ 10 6 CD34 + cells/kg had a later onset (median, day +3 vs day 0; P = 0.008) and shorter duration of neutropenia (median, 7 days vs 10 days; P Ͻ 0.001). As shown in Table  3 , in a linear regression model including these two variables, the day of G-CSF administration lacked statistical significance as a variable influencing the duration of neutropenia (P = 0.55), whereas the use of melphalan 200 mg/m 2 and a CD34
+ cell dose greater than 3.0 ϫ 10 6 /kg were significantly associated with shorter duration of neutropenia (P = 0.01 and P = 0.002, respectively).
As shown in Table 4 , in patients who received melphalan 200 mg/m 2 and more than 3.0 ϫ 10 6 CD34 + cells/kg, the duration of neutropenia was 2 days shorter in group A (P Table 5 Randomized studies evaluating the use of delayed G-CSF after autologous PBPC transplantation in adults 
Discussion
According to the most recently updated guidelines for the clinical use of hematopoietic growth factors published by the American Society of Clinical Oncology (ASCO), the optimal timing and duration of growth factor therapy after autologous PBPC transplantation remain under investigation. 25 In the present study, we observed that recipients of autologous PBPC transplants who received G-CSF starting on day +1 had a slightly shorter median duration of neutropenia when compared to patients who started G-CSF on day +5. However, after stratified analysis, the beneficial effect was evident only in patients who had been conditioned with melphalan, and received more than 3.0 ϫ 10 6
CD34
+ cells/kg. In a multivariate regression analysis that included these two variables, the day of G-CSF initiation did not influence the duration of neutropenia.
Seven randomized studies have evaluated different times for starting G-CSF in PBPC transplantation (Table 5) . Although the absolute number of days with neutropenia is the single most important variable associated with infection, this variable was analyzed in only one study, in which G-CSF was not given to the control subjects. 26 On the other hand, in agreement with other studies, [17] [18] [19] 27 ,28 the time to neutrophil engraftment, measured from the day of the transplant, was not different between the study arms, occurring around days +10 and +11.
Among the various conditioning regimens used in the present study, melphalan 200 mg/m 2 was associated with the latest onset of neutropenia after PBPC reinfusion. This was not an unexpected finding, because melphalan is known to induce neutropenia slowly, and its infusion is started very close to the day of the transplant, on day −2. Interestingly, patients who received more than 3.0 ϫ 10 6
+ cells/kg also entered the neutropenic phase later than those who received cell doses below this value (data not shown). Taken together, these findings suggest that the beneficial effect of early G-CSF initiation in reducing the duration of neutropenia might be to delay the onset of neutropenia, and not only to accelerate neutrophil engraftment. This delay could have been caused by the presence of a larger amount of G-CSF-responsive, late neutrophilic progenitors at the time of G-CSF initiation. Interestingly, in a randomized study investigating a 'patient-dependent' delayed G-CSF schedule based on peripheral leukocyte counts, where patients started receiving G-CSF only when their ANC was below 0.5 ϫ 10 9 /l, Cetkovský et al 18 commented on the occurrence of leukocytosis in the first days of G-CSF administration in patients who had received regimens which induce neutropenia slowly.
The incidence and duration of fever were similar in both groups, suggesting that in the setting of autologous PBPC transplantation, where the usual duration of neutropenia is relatively short, the true clinical impact of a 1-day reduction in neutropenia on these variables is probably small. Patients who received G-CSF on day +5 had a significantly longer duration of antibiotic treatment, but this may be explained by the higher percentage of bacteremic episodes observed in this group, since bacteremic patients usually receive a fixed course of antibiotics for 10 to 14 days, and patients who recover from neutropenia and do not have documentation of infection have the antibiotic regimen discontinued.
The median duration of hospitalization was slightly longer in group B. However, in a Cox regression analysis including other variables such as duration of neutropenia, time to neutrophil engraftment, duration of antibiotic treatment and bacteremia, the variables most associated with duration of hospitalization were duration of antibiotic treatment and time to neutrophil engraftment (data not shown).
This study has some limitations. First, our sample size was calculated to detect a 2-day difference in the duration of neutropenia. According to the updated ASCO guidelines for the use of CSFs, 25 the duration of neutropenia, when used as an outcome variable in clinical trials, is at best an indirect marker of the potential benefit of using a CSF after myelosuppressive treatment, and should always be correlated with more relevant clinical variables, such as reduction in the incidence, morbidity and mortality related to infection, duration of hospitalization, reduction in transfusion and antibiotic use, and in the cost of treatment. In order to reach statistical significance for the 11% difference in the incidence of bacteremia that was observed in the present study, aproximately 300 patients would be needed in each arm.
Despite these limitations, this study showed that patients who receive conditioning with melphalan 200 mg/m 2 and more than 3.0 ϫ 10 6 CD34 + cells/kg may take advantage of starting G-CSF on day +1, instead of day +5 after autologous PBPC transplantation. In other subgroups of patients, postponing G-CSF initiation in 5 days does not seem to be clinically relevant and may reduce the costs of the procedure.
